Elevated second-trimester maternal serum hcg alone or in combination with elevated alpha-fetoprotein

Obstetrics and Gynecology

Volumn 87, Issue 2, 1996, Pages 217-222

  Benn, Peter A ^a,b   Horne, Donna ^a,b   Briganti, Susan ^a,b   Rodis, John F ^a,b   Clive, Jonathan M ^a,b  

^a Division of Maternal Fetal Medicine   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN;

ADULT; ARTICLE; CHROMOSOME ABERRATION; CONTROLLED STUDY; DIAGNOSIS; DIAGNOSTIC VALUE; EPIDEMIOLOGY; FEMALE; FETUS MALFORMATION; HIGH RISK POPULATION; HORMONE BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MATERNAL BLOOD; NEWBORN; PREGNANCY COMPLICATION; PRIORITY JOURNAL; RISK FACTOR; SECOND TRIMESTER PREGNANCY;

EID: 0030067501     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1080/00006250-199602000-00012     Document Type: Article

References (26)

1. Cuckle HS, Wald NJ, Lindenbaum RH. Maternal serum alpha-fetoprotein measurement: A screening test for Down syndrome. Lancet 1984;1:926-9.
2. Bogart MH, Pandian MR, Jones OW. Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities. Prenat Diagn 1987;7:623-30.
3. Canick JA, Knight GJ, Palomaki GE, Haddow JE, Cuckle HS, Wald NJ. Low second trimester maternal serum unconjugated oestriol in pregnancies with Down's syndrome. Br J Obstet Gynaecol 1988; 95:330-3.
4. Canick JA, Palomaki GE, Osathanondh R. Prenatal screening for trisomy 18 in the second trimester. Prenat Diagn 1990;10:546-8.
5. Sailer DN Jr, Canick JA, Schwartz S, Blitzer MG. Multiple marker screening in pregnancies with hydropic and nonhydropic Turner syndrome. Am J Obstet Gynecol 1992;167:1021-4.
6. Schmidt D, Shaffer L, McCaskill C, Rose E, Greenberg F. Very low maternal serum chorionic gonadotropin levels in association with fetal triploidy. Am J Obstet Gynecol 1993;170:77-80.
7. Burton BK. Unexplained elevated maternal serum alpha fetoprotein and adverse perinatal outcome. In: Elias S, Simpson JL, eds. Maternal serum screening for fetal genetic disorders. 1st ed. New York: Churchill Livingstone, 1992:109-19.
8. Nebiolo LM, Adams WB, Miller SL, Milunsky A. Maternal serum human chorionic gonadotropin levels in twin pregnancies. Prenat Diagn 1991;11:463-6.
9. Gonen R, Perez R, David M, Dar H, Merksamer R, Shart M. The association between unexplained second-trimester maternal serum hCG elevation and pregnancy complications. Obstet Gynecol 1992; 80:83-6.
10. Lieppman RE, Williams MA, Cheng EY, et al. An association between elevated levels of human chorionic gonadotropin in the midtrimester and adverse pregnancy outcome. Am J Obstet Gynecol 1993;168:1852-7.
11. Wenstrom KD, Owen J, Boots LR, DuBard MB. Elevated second-trimester human chorionic gonadotropin levels in association with poor pregnancy outcome. Am J Obstet Gynecol 1994;171:1038-41.
12. Sorensen TK, Williams MA, Zingheim RW, Clement SJ, Hickok DE. Elevated second-trimester human chorionic gonadotropin and subsequent pregnancy-induced hypertension. Am J Obstet Gynecol 1993;169:834-8.
13. Gravett CP, Buckmaster JG, Watson PT, Gravett MG. Elevated second trimester maternal serum /3-hCG concentrations and subsequent adverse pregnancy outcome. Am J Med Genet 1992;44: 485-6.
14. Muller F, Aegerter P, Boue A. Prospective maternal serum human chorionic gonadotropin screening for the risk of fetal chromosome anomalies and of subsequent fetal and neonatal deaths. Prenat Diagn 1993;13:29-43.
15. Beekhuis JR, Van Lith JMM, De Wolf THM, Mantingh A. Increased maternal serum alpha-fetoprotein and human chorionic gonadotropin in compromised pregnancies other than for neural tube defects or Down syndrome. Prenat Diagn 1992;12:643-47.
16. Bradley LA, Horwitz JA, Dowman AC, Ponting NR, Peterson LM. Triple marker screening for fetal Down syndrome. Int Ped 1994;9: 168-74.
17. Benn PA, Home D, Briganti S, Greenstein RM. Prenatal diagnosis of diverse chromosome abnormalities in a population of patients identified by triple-marker testing as screen-positive for Down syndrome. Am J Obstet Gynecol 1995;173:496-501.
18. Williams RL, Creasy RK, Cunningham GC, Hawes WE, Norris FD, Tashiro M. Fetal growth and perinatal viability in California. Obstet Gynecol 1982;59:624-32.
19. Hosmer DW, Lemeshow S. Applied logistic regression. New York: John Wiley & Sons, 1989.
20. Milunsky A, Jick SS, Bruell CL, et al. Predictive values, relative risks, and overall benefits of high and low maternal serum alpha-fetoprotein screening in singleton pregnancies: New epidemiologic data. Am J Obstet Gynecol 1989;161:291-7.
21. Crandall BF, Robinson L, Grau P. Risks associated with an elevated maternal serum alpha-fetoprotein. Am J Obstet Gynecol 1991;165: 581-6.
22. McCormick MC. The contribution of low birth weight to infant mortality and childhood morbidity. New Engl J Med 1985;312:82-90.
23. Simpson JL, Elias S, Morgan CD, Shulman L, Umstot E, Andersen RN. Second-trimester maternal serum human chorionic gonadotropin and unconjugated oestriol levels in blacks and whites. Lancet 1990;335:1459-60.
24. Lee KS, Ferguson RM, Corpuz M, Gartner LM. Maternal age and incidence of low birth weight at term: A population study. Am J Obstet Gynecol 1988;158:84-9.
25. Crosignani PG, Trojsi L, Attanasio AE. Value of hCG and hCS measurement in clinical practice. Obstet Gynecol 1974;44:673-81.
26. Boue J, Boue A, Lazar P. Retrospective and prospective epidemiological studies of 1500 karyotyped spontaneous human abortions. Teratology 1975;12:11-26.